Cellular Senescence & Senolytics
Aging biology | Senescence • Senolytics • Early translation
Common names: cellular senescence · senolytics · senescent cells · SASP · senescence-associated secretory phenotype
- Evidence searched through
- August 24, 2026
- Last reviewed
- August 24, 2026
- Current version
- 1.0
4V Take
What the research shows.
Senescent cells are cells that have stopped dividing but can remain active and release signals into nearby tissue. In animals, drugs designed to remove some of those cells can improve several age-related problems. Early human studies show some biological changes too. What we do not know yet is whether senolytics extend human lifespan, reverse aging or make sense for healthy people.
Explore the evidenceResearch Interest
Why are people interested?
Researchers are studying Cellular Senescence & Senolytics across the approved public questions in this record. Those questions are areas of research interest, not guaranteed outcomes.
Evidence Context
What have researchers looked at?
This approved record brings together the research settings represented in its selected public sources. Evidence settings answer different questions, so human, animal, laboratory, and research-review findings stay distinct.
Current research context
Research stage describes the maturity of the current topic record. Source context describes the evidence settings represented in the selected public sources below; they are not interchangeable.
- Research stage
- Early Clinical / Developing
- Selected source context
- Human · Mixed · Research Review
At a Glance
Research snapshot.
- 01Human Research
Small early studies - 02Research Stage
Early Clinical / Developing - 03Key Distinction
Biomarkers ≠ clinical efficacy - 04Healthy-Aging Benefit
Not established
Research Pathway
Follow the questions.
Choose a pathway to read its approved 4V Take. Each view stays focused on one question at a time.
4V Take
Senescent cells can accumulate with aging and chronic disease and can produce a pro-inflammatory/pro-fibrotic secretory phenotype.
- Evidence bucket
- mixed
- Research stage
- developing clinical
- Route / format
- Not applicable
Explore the evidence
human direct
Hickson LJ et al. Senolytics decrease senescent cells in humans: preliminary diabetic-kidney-disease trial. EBioMedicine. 2019.
human direct
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: randomized placebo-controlled pilot.
human synthesis
Strategies for late-phase preclinical and early clinical trials of senolytics.
4V Take
A small open-label study in nine people with diabetic kidney disease found reduced senescent-cell markers in adipose/skin after short intermittent dasatinib + quercetin treatment.
- Evidence bucket
- human clinical
- Research stage
- developing clinical
- Route / format
- Not applicable
Explore the evidence
human direct
Hickson LJ et al. Senolytics decrease senescent cells in humans: preliminary diabetic-kidney-disease trial. EBioMedicine. 2019.
human direct
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: randomized placebo-controlled pilot.
human synthesis
Strategies for late-phase preclinical and early clinical trials of senolytics.
4V Take
A 12-person randomized placebo-controlled pilot in idiopathic pulmonary fibrosis found intermittent dasatinib + quercetin feasible, but was underpowered for efficacy and did not show meaningful between-group functional differences.
- Evidence bucket
- human clinical
- Research stage
- developing clinical
- Route / format
- Not applicable
Explore the evidence
human direct
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: randomized placebo-controlled pilot.
human direct
Hickson LJ et al. Senolytics decrease senescent cells in humans: preliminary diabetic-kidney-disease trial. EBioMedicine. 2019.
human synthesis
Strategies for late-phase preclinical and early clinical trials of senolytics.
4V Take
Senolytic effects are agent-, cell-type-, tissue-, and context-dependent; “senolytic” is not one uniform treatment class.
- Evidence bucket
- mixed
- Research stage
- developing clinical
- Route / format
- Not applicable
Explore the evidence
human direct
Hickson LJ et al. Senolytics decrease senescent cells in humans: preliminary diabetic-kidney-disease trial. EBioMedicine. 2019.
human direct
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: randomized placebo-controlled pilot.
human synthesis
Strategies for late-phase preclinical and early clinical trials of senolytics.
4V Take
Candidate senolytics can have meaningful drug-specific risks; dasatinib is not equivalent to a benign longevity supplement.
- Evidence bucket
- mixed
- Research stage
- developing clinical
- Route / format
- Not applicable
Explore the evidence
human direct
Hickson LJ et al. Senolytics decrease senescent cells in humans: preliminary diabetic-kidney-disease trial. EBioMedicine. 2019.
human direct
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: randomized placebo-controlled pilot.
human synthesis
Strategies for late-phase preclinical and early clinical trials of senolytics.
4V Take
Human evidence does not establish senolytics as a proven intervention to extend lifespan or broadly reverse aging in healthy adults.
- Evidence bucket
- mixed
- Research stage
- developing clinical
- Route / format
- Not applicable
Explore the evidence
human direct
Hickson LJ et al. Senolytics decrease senescent cells in humans: preliminary diabetic-kidney-disease trial. EBioMedicine. 2019.
human direct
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: randomized placebo-controlled pilot.
human synthesis
Strategies for late-phase preclinical and early clinical trials of senolytics.
Selected Sources
Explore the evidence.
Open an approved public source to inspect its study context, limitations, and original record where available.
human direct
Hickson LJ et al. Senolytics decrease senescent cells in humans: preliminary diabetic-kidney-disease trial. EBioMedicine. 2019.
2019 · PMID: 31542391 · peer reviewed
human direct
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: randomized placebo-controlled pilot.
2023 · PMID: 36857968 · peer reviewed
human synthesis
Strategies for late-phase preclinical and early clinical trials of senolytics.
2021 · PMID: 34699859 · peer reviewed
Research Status
Living research, deliberately tracked.
- Evidence searched globally through:
- August 24, 2026
- Last reviewed
- August 24, 2026
- Version
- 1.0
What Changed
Current record.
No later approved public release is available beyond the current topic record.
Evidence Boundaries
What are researchers still working out?
Study settings, measures, and limitations matter. A mechanism does not establish an outcome, animal or laboratory findings do not establish a human benefit, and a small study does not create consensus. Open each selected source for the approved record behind its finding.
Related Research
Continue with context.
Connections are limited to approved topic context. Each linked topic keeps its own evidence boundaries and Research Stage.
Save / Follow
Keep this research close.
Save and Follow remain private account preferences. Following does not activate monitoring or notifications.
Loading member research actions.